Guggenheim Upgrades BeiGene to Buy, Announces $205 Price Target
Guggenheim analyst Michael Schmidt upgrades BeiGene (NASDAQ:BGNE) from Neutral to Buy and announces $205 price target.
BeiGene’s Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
BeiGene Limited (NASDAQ:BGNE) shared updates from its solid tumor development program for tislelizumab at the European Society for Medical Oncology (ESMO)…
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
Key Takeaways:
The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million
Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the company has still not yet filed an application to market the product
By Molly Wen
Catalent, Tellurian And Other Big Losers From Monday
U.S. stocks closed lower with the Dow Jones dropping around 185 points on Monday. Here is the list of some big stocks moving lower in the previous session.
Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket
Gainers
ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading.
Tesla, Autodesk And Some Other Big Stocks Moving Higher In Today’s Pre-Market Session
Snowflake Inc. (NYSE: SNOW) surged 17.4% to $187.18 in pre-market trading after the company reported better-than-expected Q2 sales results and issued product revenue guidance.
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck‘s (NYSE:MRK) lead asset MK-2060…
Recap of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset…
JP Morgan Assumes BeiGene at Overweight, Announces Price Target of $296
JP Morgan analyst Xiling Chen assumes BeiGene (NASDAQ:BGNE) with a Overweight rating and announces Price Target of $296.